Fill-Finish Manufacturing Market Report 2024-2034

Visiongain has published a new report entitled Fill-Finish Manufacturing Market Report 2024-2034: Forecasts by Product (Instruments, Consumables), by Instrument (System Type (Integrated System, Standalone System), Machine Type (Automated Machine, Semi-automated Machine, Manual Machine)), by Consumables (Pre-filled Syringes, Pre-filled Vials, Pre-filled Cartridges, Pre-filled Packaging, Other), by End-users (Contract Manufacturing Organisations (CMOs), Pharmaceutical Companies, Biopharmaceutical Companies, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global Fill Finish Manufacturing market is estimated at US$11,065.8 million in 2024 and is projected to grow at a CAGR of 9.7% during the forecast period 2024-2034.

Technological Advancements in Fill Finish Manufacturing Processes

Technological advancements in fill and finish manufacturing processes such as automation is a rising trend as a way to reduce time to market and enhance efficiency Some of the emerging technologies are automation and robotics, and novel aseptic techniques A sterile fill finish requires both aseptic liquid filling and aseptic vial filling. The fill finish process will benefit from newly developed aseptic procedures that seek to raise the level of sterility assurance. Isolator technology and limited access barrier systems (RABS) are examples of advancements that help ensure the safety, integrity, and compliance of products with regulations. Robotic systems can be used for inspection, cap installation, and vial handling, among other duties. Various companies are heavily investing towards robotics-based fill finish manufacturing for instances, The equipment will be used to load different sterile pharmaceuticals into vials and syringes for small to mid-scale client demands, according to a press release issued by CDMO PCI Pharma in April 2023. Furthermore, various contract manufacturers are expected to expand their capabilities, which shall be instated with state of the art and technologically advanced equipment. For example, Simtra BioPharma Solutions (Simtra), announced that its sterile fill/finish manufacturing site in Bloomington, Indiana, will be expanded for more than $250 million. Two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line with three 30-square-meter lyophilizers will be housed in a brand-new.

How will this Report Benefit you?

Visiongain’s 357-page report provides 137 tables, 203 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the Fill Finish Manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Fill Finish Manufacturing. Get financial analysis of the overall market and different segments including type, process, upstream, downstream, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing Fill Finish Manufacturing market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Increasing Demand for Fill Finish Outsourcing

Innovations in automation, integrated IT, digitization, and environmental conditioning systems are what propel the outsourcing sector. Versatile fill-finish processes are becoming more crucial as the pharmaceutical industry moves away from blockbuster drugs and toward targeted, specialized treatments for specific patient populations. These aseptic small-batch products require a quicker time to market in addition to posing unique handling, filling, and sterilization challenges. Innovations in cleanroom technology, like controlled access barrier systems and isolators, have facilitated the transition to multi-product, flexible fill-finish procedures. Although it is doubtful that single-use systems would ever completely replace stainless steel equipment in these situations, single-use technologies have been a driving factor in fill-finish operation improvements. Many of the previous sources of contamination risk are being reduced by increased automation in fill-finish equipment and facilities. Wider industry developments, such as greater digitalization, the drive toward Industry 4.0 production models, and serialisation, are changing both fill-finish processes and how they are seen in wider development and manufacturing plans. To keep up with evolving, patient-centric needs, fill-finish operations must also be adaptable.

Rising Adoption of Prefilled Syringes for Parenteral Administration

One of the most popular methods for triggering a quick immune response and ensuring that medications are fully accessible is parenteral delivery. The development and commercialization of parenteral medications have coincided with an increased demand for complex, affordable drug delivery systems that guarantee ease of administration. The fill-finish manufacturing sector's prefilled syringes division is growing quickly. Prefilled syringes have several advantages over traditional delivery systems, including convenience of administration, improved safety, precise dosage, and reduced concerns about contamination. Among drug delivery devices, prefilled syringes—which are also intended for dosage administration—are one of the key packaging formats that is expanding the fastest. The last 10 years have seen a discernible advancement in the creation of parenteral medications, especially with the advent of numerous types of biologics, which has led to an approximately three-fold increase in the use of prefilled syringes. Pre-filled syringes' enduring appeal can be attributed to their simplicity of use and safety. The features in the most recent versions reduce dosing errors, the risk of occlusions, fluid leakage (extravasation), and vein irritation.

Where are the Market Opportunities?

Advancement in Biologics Manufacturing

Rapid growth in the biologic manufacturing, the U.S. continues to lead the biotech business with the greatest number of active companies (2,840) and an R&D intensity added value of 17%. However, other countries also emerging in rapid manner, such as Belgium's remarkable 35.7% added value in biotech R&D shows a potential yet uneven biotechnology ecosystem, while the UK's strong 2023 third quarter strengthened its position as an innovation driver in Europe.

Strong growth potential in Asia Pacific region, talking about emerging nation such as India. India's pharmaceutical clusters need a robust innovation pipeline to launch new products and molecular entities on a yearly basis.

Growth in Number of First Generics

The growth in the global complex generics market indeed presents opportunities for fast-fill manufacturing. Complex generics refer to generic versions of drugs that are more challenging to develop due to their complexity, such as products with intricate formulations, delivery systems, or manufacturing processes. Fast-fill manufacturing processes are often designed to be highly efficient, minimizing production costs and maximizing profitability. This cost efficiency is particularly important in the generic drug market, where pricing pressures are high. In order to accomplish the same, the market for specialty and complex generics is now being penetrated by industry.

Competitive Landscape

The major players operating in the Fill Finish Manufacturing market are AbbVie Inc., Aseptic Technologies, Bausch + Ströbel, Becton, Dickinson and Company (BD), Catalent Inc., Gerresheimer AG, Groninger & Co. GmbH, I.M.A. Industria Macchine Automatiche S.P.A, Mabion S.A., Marchesini Group S.p.A., Nipro Corporation, Optima Packaging Group GmbH, Piramal Pharma Solutions, Recipharm AB, Schott AG, Steriline, Stevanato Group, Symbiosis Pharmaceutical Service, Vanrx Pharmasystems Inc. (Cytiva), West Pharmaceutical Services, Inc. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.

Recent Developments

• On 4th December 2023, West Pharmaceutical Services Inc., released a new product offering in their fill finish unit, Vial2Bag Advanced® 13mm admixture device, portraying their dedication to innovation in their injectable solutions product line.
• On 31st October 2023, Gerresheimer AG announced their partnership with Rezemo. Rezemo would be their supplier of bio-based closure materials for packaging of their finish products, showcasing their involvement in environmental and sustainability goals set out by the UN.
• On 2nd June 2023, BD invested US$33 million in their Ireland manufacturing plant at Wexford which shall focus on their business for Peripheral Intervention. This expansion would be about 40,000 sq. ft at their existing plant.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.